Imatynib w terapii adiuwantowej pacjentów po zabiegu usunięcia nowotworów podścieliskowych przewodu pokarmowego (GIST) – przegląd systematyczny badań klinicznych i metaanaliza Original article
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2013
Słowa kluczowe:
nowotwór podścieliskowy przewodu pokarmowego, GIST, imatynib, leczenie adiuwantowe, przegląd systematyczny
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wstęp: Zastosowanie terapii adiuwantowej jest zalecane u pacjentów ze znaczącym ryzykiem nawrotu choroby po zabiegu usunięcia nowotworu podścieliskowego przewodu pokarmowego.
Cel pracy: Ocena skuteczności klinicznej i profilu bezpieczeństwa imatynibu stosowanego w ramach terapii adiuwantowej u pacjentów po zabiegu całkowitej resekcji nowotworu podścieliskowego przewodu pokarmowego.
Materiał i metody: Przeprowadzono systematyczny przegląd literatury opublikowanej do 30 marca 2012 r. oraz metaanalizę zakwalifikowanych do opracowania badań. Przeszukano następujące bazy danych: PubMed, EMBASE, The Cochrane Library oraz inne.
Wyniki: Odnaleziono 2 randomizowane badania kliniczne, dotyczące porównania: imatynibu z placebo oraz imatynibu stosowanego przez 12 miesięcy z imatynibem podawanym przez 36 miesięcy, oraz 20 nierandomizowanych badań klinicznych dotyczących stosowania imatynibu w analizowanym wskazaniu. Zastosowanie imatynibu w terapii adiuwantowej prowadzi do istotnego statystycznie wydłużenia przeżycia wolnego od nawrotu choroby względem placebo. Największe korzyści z zastosowanej terapii odnoszą chorzy z wysokim ryzykiem nawrotu choroby. Przedłużenie 12-miesięcznej terapii imatynibem do 36 miesięcy zwiększa prawdopodobieństwo przeżycia wolnego od progresji choroby oraz przeżycia całkowitego pacjentów po zabiegu resekcji nowotworu podścieliskowego przewodu pokarmowego. Profil bezpieczeństwa imatynibu w analizowanej populacji okazał się korzystny.
Wnioski: U pacjentów o znaczącym ryzyku nawrotu terapia adiuwantowa imatynibem powinna być rozpatrywana w przypadku każdego pacjenta ze względu na korzyści kliniczne, jakie przynosi.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Kawalec P, Kryst J, Laczewski T, Martyna L. Imatynib w terapii adiuwantowej pacjentów po zabiegu usunięcia nowotworów podścieliskowych przewodu pokarmowego (GIST) – przegląd systematyczny badań klinicznych i metaanaliza. OncoReview [Internet]. 31 grudzień 2013 [cytowane 4 lipiec 2024];3(4(12):232-4. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/347
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Głuszek S., Rylski R., Kot M. et al.: GIST – ryzyko nawrotu i rozsiewu na podstawie obserwacji własnych. Prz. Gastroenterol. 2008; 3(4): 176-184.
2. Rutkowski P., Nowecki Z., Ruka W.: Nowotwory podścieliskowe przewodu pokarmowego (GIST). W: Zalecenia postępowania diagnostycznoterapeutycznego w nowotworach złośliwych. Krzakowski M. (red.). Via Medica, Gdańsk 2009.
3. Ługowska I.: Mięsaki tkanek miękkich i kości oraz GIST – relacja z konferencji naukowej: ESMO Conference on Sarcoma and GIST, 9–10 marca 2012, Mediolan, Włochy. Oncorev. 2012; 2(2): 103-110.
4. Zaniewski M., Smyła Z., Piekorz P. et al.: Podścieliskowe guzy przewodu pokarmowego (GIST). Chir. Pol. 2004; 6(4): 253-259.
5. Wilson J., Connock M., Song F. et al.: Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol. Assess. 2005; 9(25): 1-142.
6. Rutkowski P., Nowecki Z.: Aspekty molekularno-kliniczne nowotworów podścieliskowych przewodu pokarmowego. Onkol. Prakt. Klin. 2009; 5(6): 219-228.
7. Fletcher C., Berman J., Corless C. et al.: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002; 33(5): 459-465.
8. Dirnhofer S., Leyvraz S.: Current standards and progress in understanding and treatment of GIST. Swiss Med. Wkly 2009; 139(7-8): 90-102.
9. Joensuu H.: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 2008; 39(10): 1411-1419.
10. Miettinen M., Lasota J.: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006; 130(10): 1466-78.
11. Rutkowski P., Kulig J., Krzakowski M. et al.: Zasady postępowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST) w 2010 roku. Onkol. Prakt. Klin. 2010; 6(4): 181-194.
12. Ruka W., Rutkowski P., Zdzienicki M., Nowecki Z.: Leczenie chirurgiczne nowotworów podścieliskowych przewodu pokarmowego (GIST). Gastroenterol. Pol. 2009; 16(2): 129-134.
13. Rutkowski P., Nowecki Z., Michej W. et al.: Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann. Surg. Oncol. 2007; 14(7): 2018-27.
14. Essat M., Cooper K.: Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int. J. Cancer 2011; 128(9): 2202-2214.
15. Rutkowski P.: Nowotwory podścieliskowe przewodu pokarmowego. Gastroenterol. Klin. 2011; 3(3): 127-135.
16. National Institute for Clinical Excellence. Imatinib for the treatment of unresectable and/or metasatic gastrointestinal stromal tumours. Technology Appraisal 86, NICE, London, 2004.
17. Charakterystyka Produktu Leczniczego Glivec®. Online: http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125 (Access: march 2012).
18. DeMatteo R., Ballman K., Antonescu C. et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373(9669): 1097-1104.
19. DeMatteo R., Owzar K., Maki R. et al.: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. 2007 ASCO Annual Meeting, abstrakt nr 10079.
20. Online: http://www.clinicaltrials.gov/ct2/show/NCT00041197... (Access: march 2012).
21. Cohen M., Cortazar P., Justice R., Pazdur R.: Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist 2010; 15(3): 300-307.
22. Wytyczne Cochrane Collaboration. Online: www.cochrane.org (Access: march 2012).
23. Joensuu H., Eriksson M., Sundby Hall K. et al.: One vs three years of adjuwant imatinib for operable gastrointestinal stromal tumor. A randomized trial. JAMA 2012; 307(12): 1265-1272.
24. Joensuu H., Eriksson M., Hatrmann J. et al.: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J. Clin. Oncol. 2011; 29(suppl.): abstrakt nr LBA1.
25. Blanke C.: Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors. JAMA 2012; 307(12): 1312-1314.
26. Online: http://www.clinicaltrials.gov/ct2/show/NCT00116935... (Access: march 2012).
27. Li J., Gong J., Wu A., Shen L.: Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur. J. Surg. Oncol. 2011; 37(4): 319-324.
28. Li J., Gong J., Li J., Wu A., Shen L.: Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: Analysis from a single-center contrast study. 2009 ASCO Annual Meeting, abstrakt nr 10556.
29. Shen L., Li J., Li J., Gong J., Wu A.: Adjuvant post-surgery therapy with imatinib in intermediate or high-risk gastrointestinal stromal tumour (GIST) patients: interim analysis from a single centre comparison study. Ann. Oncol. 2008; 19(suppl.8): 267.
30. Jiang W., Guan G., Lu., Yang Y., Kang D., Huang H.: Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J. Surg. Oncol. 2011; 104(7): 760-764.
31. Nilsson B., Sjölund K., Kindblom L. et al.: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br. J. Cancer 2007; 96(11): 1656-1658.
32. DeMatteo R., Antonescu C., Chadaram V. et al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup Phase II trial ACOSOG Z9000. J. Clin. Oncol. 2005; 23(suppl.): abstrakt 16S.
33. DeMatteo R., Owzar K., Antonescu C. et al.: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 Abstract. ASCO 2008 GI Cancer Symposium, abstrakt nr FL. A-8.
34. Online: http://www.clinicaltrials.gov/ct2/show/NCT00025246... (Access: march 2012).
35. Kang Y., Kang B., Ryu M. et al.: A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors with C-Kit exon 11 mutation. ASCO 2009 GI Cancer Symposium, abstrakt nr 95.
36. Kang B., Lee J., Ryu M. et al.: A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J. Clin. Oncol. 2009; 27(suppl.): e21515.
37. Online: http://www.clinicaltrials.gov/ct2/show/NCT00278876... (Access: march 2012).
38. Zhan W., Wang P., Shao Y. et al.: Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial. Zhonghua Wei Chang Wai Ke Za Zhi 2006; 9(5): 383-387.
39. Zhan W.: Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing gastrointestinal stromal tumor. J. Clin. Oncol. 2007; 25(suppl.): abstrakt nr 10045.
40. Nishida T., Kanda T., Wada N. et al.: Phase II trial of adjuvant imatinib mesylate after resection of localized, primary high risk gastrointestinal stromal tumour (GIST) in Japan. Eur. J. Cancer 2009; suppl. 7(2): 593.
41. Online: http://www.clinicaltrials.gov/ct2/show/NCT00171977?term=NCT00171977... (Access: march 2012).
42. Online: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do? trialResult=3560 (Access: march 2012).
43. Bümming P., Andersson J., Meis-Kindblom J. et al.: Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br. J. Cancer 2003; 89(3): 460-464.
44. Shi Y., Du C., Zhou Y.: Efficacy and safety of the imatinib in the treatment of 73 gastrointestinal stromal tumors. J. Clin. Oncol. 2008; 26(suppl.): abstrakt nr 21512.
45. Hatoum T., Trent J., Guo A., Lin S., Sirulnik A., Sasane M.: Outcome of adjuvant imatinib in patients with gastrointestinal stromal tumor: Results of a population-based, matched cohort study. J. Clin. Oncol. 2011; 29(suppl.): abstrakt 10052.
46. Trent J., von Mehren M., Pisters P., Stealey E., Sirulnik L., Blanke C.: Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST) patients: Dose, duration, and risk assessment. J. Clin. Oncol. 2010; 28(suppl.): abstrakt nr 10061.
47. Manouras A., Pappas A., Katergiannakis V. et al.: Gastrointestinal Stromal Tumors or the rectum: report of five cases. Acta Gastroenterol. Belg. 2009; 72(2): 257-261.
48. Cruz Jr R., Vincenzi R., Ketzer B., Cecilio A., Cepeda L.: Spontaneous intratumoral bleeding and rupture of giant gastric stromal tumor (> 30 cm) in a young patient. World J. Surg. Oncol. 2008; 6: 76.
49. Armbrust T., Sobotta M., Ramadori G.: Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with imatinib. Ann. Oncol. 2007; 18(6): 1123-1125.
50. Bogoevski D., Mann O., Schurr P., Izbicki J., Strate T.: Laparoscopic gastric tailoring for huge subcardial gastrointestinal stromal tumor. JSLS 2007; 11(3): 394-397.
51. Osada T., Nagahara A., Kodani T. et al.: Gastrointestinal stromal tumor of the stomach with a giant abscess penetrating the gastric lumen. World J. Gastroenterol. 2007; 13(16): 2385-2387.
52. Efremidou E., Liratzopoulos N., Papageorgiou M., Romanidis K., Manolas K., Minopoulos G.: Perforated GIST of the small intestine as a rare cause of acute abdomen: surgical treatment and adjuvant therapy. Case report. J. Gastrointestin. Liver Dis. 2006; 15(3): 297-299.
53. Ferraresi V., Catricala C., Ciccarese M., Ferrari A., Zeuli M., Cognetti F.: Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. Anticancer Res. 2006; 26(6C): 4771-4774.
54. Lai I., Hu R., Chang K.: Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors. Hepatogastroenterology 2005; 52(63): 826-828.
55. Cunningham S., Shibata D., Volpe C.: Isolated abdominal wound metastasis from a gastrointestinal stromal tumor. Int. J. Gastrointest. Cancer 2003; 33(2-3): 129-132.
56. Online: http://www.clinicaltrials.gov/ct2/show/NCT00867113... (Access: march 2012).
57. Online: http://www.clinicaltrials.gov/ct2/show/NCT01172548... (Access: march 2012).
58. Online: http://www.clinicaltrials.gov/ct2/show/NCT00103168... (Access: march 2012).
59. Online: http://cancer.gov/clinicaltrials/search/view?cdrid=410825&version= healthprofessional (Access: march 2012)
60. Nilsson B., Bümming P., Meis-Kindblom J. et al.: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer 2005; 103(4): 821-829.
61. DeMatteo R., Lewis J., Leung D., Mudan S., Woodruff J., Brennan M.: Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000; 231(1): 51-57.
62. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. National Institute for Health and Clinical Excellence (NICE) technology appraisal guidance 196. Sierpień 2010.
63. Online: http://www.novartis.com/newsroom/media-releases/en/2012/1579137.shtml (Access: march 2012).
64. von Mehren M., Benjamin R., Bui M. et al.: NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 2.2011.
65. Hou Y., Grabellus F., Weber F. et al.: Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection. J. Gastrointest. Surg. 2009; 13(9): 1583-1592.
66. Heinrich M., Corless C., Demetri G. et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21(23): 4342-4349.
2. Rutkowski P., Nowecki Z., Ruka W.: Nowotwory podścieliskowe przewodu pokarmowego (GIST). W: Zalecenia postępowania diagnostycznoterapeutycznego w nowotworach złośliwych. Krzakowski M. (red.). Via Medica, Gdańsk 2009.
3. Ługowska I.: Mięsaki tkanek miękkich i kości oraz GIST – relacja z konferencji naukowej: ESMO Conference on Sarcoma and GIST, 9–10 marca 2012, Mediolan, Włochy. Oncorev. 2012; 2(2): 103-110.
4. Zaniewski M., Smyła Z., Piekorz P. et al.: Podścieliskowe guzy przewodu pokarmowego (GIST). Chir. Pol. 2004; 6(4): 253-259.
5. Wilson J., Connock M., Song F. et al.: Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol. Assess. 2005; 9(25): 1-142.
6. Rutkowski P., Nowecki Z.: Aspekty molekularno-kliniczne nowotworów podścieliskowych przewodu pokarmowego. Onkol. Prakt. Klin. 2009; 5(6): 219-228.
7. Fletcher C., Berman J., Corless C. et al.: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002; 33(5): 459-465.
8. Dirnhofer S., Leyvraz S.: Current standards and progress in understanding and treatment of GIST. Swiss Med. Wkly 2009; 139(7-8): 90-102.
9. Joensuu H.: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 2008; 39(10): 1411-1419.
10. Miettinen M., Lasota J.: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006; 130(10): 1466-78.
11. Rutkowski P., Kulig J., Krzakowski M. et al.: Zasady postępowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST) w 2010 roku. Onkol. Prakt. Klin. 2010; 6(4): 181-194.
12. Ruka W., Rutkowski P., Zdzienicki M., Nowecki Z.: Leczenie chirurgiczne nowotworów podścieliskowych przewodu pokarmowego (GIST). Gastroenterol. Pol. 2009; 16(2): 129-134.
13. Rutkowski P., Nowecki Z., Michej W. et al.: Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann. Surg. Oncol. 2007; 14(7): 2018-27.
14. Essat M., Cooper K.: Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int. J. Cancer 2011; 128(9): 2202-2214.
15. Rutkowski P.: Nowotwory podścieliskowe przewodu pokarmowego. Gastroenterol. Klin. 2011; 3(3): 127-135.
16. National Institute for Clinical Excellence. Imatinib for the treatment of unresectable and/or metasatic gastrointestinal stromal tumours. Technology Appraisal 86, NICE, London, 2004.
17. Charakterystyka Produktu Leczniczego Glivec®. Online: http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125 (Access: march 2012).
18. DeMatteo R., Ballman K., Antonescu C. et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373(9669): 1097-1104.
19. DeMatteo R., Owzar K., Maki R. et al.: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. 2007 ASCO Annual Meeting, abstrakt nr 10079.
20. Online: http://www.clinicaltrials.gov/ct2/show/NCT00041197... (Access: march 2012).
21. Cohen M., Cortazar P., Justice R., Pazdur R.: Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist 2010; 15(3): 300-307.
22. Wytyczne Cochrane Collaboration. Online: www.cochrane.org (Access: march 2012).
23. Joensuu H., Eriksson M., Sundby Hall K. et al.: One vs three years of adjuwant imatinib for operable gastrointestinal stromal tumor. A randomized trial. JAMA 2012; 307(12): 1265-1272.
24. Joensuu H., Eriksson M., Hatrmann J. et al.: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J. Clin. Oncol. 2011; 29(suppl.): abstrakt nr LBA1.
25. Blanke C.: Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors. JAMA 2012; 307(12): 1312-1314.
26. Online: http://www.clinicaltrials.gov/ct2/show/NCT00116935... (Access: march 2012).
27. Li J., Gong J., Wu A., Shen L.: Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur. J. Surg. Oncol. 2011; 37(4): 319-324.
28. Li J., Gong J., Li J., Wu A., Shen L.: Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: Analysis from a single-center contrast study. 2009 ASCO Annual Meeting, abstrakt nr 10556.
29. Shen L., Li J., Li J., Gong J., Wu A.: Adjuvant post-surgery therapy with imatinib in intermediate or high-risk gastrointestinal stromal tumour (GIST) patients: interim analysis from a single centre comparison study. Ann. Oncol. 2008; 19(suppl.8): 267.
30. Jiang W., Guan G., Lu., Yang Y., Kang D., Huang H.: Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J. Surg. Oncol. 2011; 104(7): 760-764.
31. Nilsson B., Sjölund K., Kindblom L. et al.: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br. J. Cancer 2007; 96(11): 1656-1658.
32. DeMatteo R., Antonescu C., Chadaram V. et al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup Phase II trial ACOSOG Z9000. J. Clin. Oncol. 2005; 23(suppl.): abstrakt 16S.
33. DeMatteo R., Owzar K., Antonescu C. et al.: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 Abstract. ASCO 2008 GI Cancer Symposium, abstrakt nr FL. A-8.
34. Online: http://www.clinicaltrials.gov/ct2/show/NCT00025246... (Access: march 2012).
35. Kang Y., Kang B., Ryu M. et al.: A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors with C-Kit exon 11 mutation. ASCO 2009 GI Cancer Symposium, abstrakt nr 95.
36. Kang B., Lee J., Ryu M. et al.: A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J. Clin. Oncol. 2009; 27(suppl.): e21515.
37. Online: http://www.clinicaltrials.gov/ct2/show/NCT00278876... (Access: march 2012).
38. Zhan W., Wang P., Shao Y. et al.: Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial. Zhonghua Wei Chang Wai Ke Za Zhi 2006; 9(5): 383-387.
39. Zhan W.: Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing gastrointestinal stromal tumor. J. Clin. Oncol. 2007; 25(suppl.): abstrakt nr 10045.
40. Nishida T., Kanda T., Wada N. et al.: Phase II trial of adjuvant imatinib mesylate after resection of localized, primary high risk gastrointestinal stromal tumour (GIST) in Japan. Eur. J. Cancer 2009; suppl. 7(2): 593.
41. Online: http://www.clinicaltrials.gov/ct2/show/NCT00171977?term=NCT00171977... (Access: march 2012).
42. Online: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do? trialResult=3560 (Access: march 2012).
43. Bümming P., Andersson J., Meis-Kindblom J. et al.: Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br. J. Cancer 2003; 89(3): 460-464.
44. Shi Y., Du C., Zhou Y.: Efficacy and safety of the imatinib in the treatment of 73 gastrointestinal stromal tumors. J. Clin. Oncol. 2008; 26(suppl.): abstrakt nr 21512.
45. Hatoum T., Trent J., Guo A., Lin S., Sirulnik A., Sasane M.: Outcome of adjuvant imatinib in patients with gastrointestinal stromal tumor: Results of a population-based, matched cohort study. J. Clin. Oncol. 2011; 29(suppl.): abstrakt 10052.
46. Trent J., von Mehren M., Pisters P., Stealey E., Sirulnik L., Blanke C.: Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST) patients: Dose, duration, and risk assessment. J. Clin. Oncol. 2010; 28(suppl.): abstrakt nr 10061.
47. Manouras A., Pappas A., Katergiannakis V. et al.: Gastrointestinal Stromal Tumors or the rectum: report of five cases. Acta Gastroenterol. Belg. 2009; 72(2): 257-261.
48. Cruz Jr R., Vincenzi R., Ketzer B., Cecilio A., Cepeda L.: Spontaneous intratumoral bleeding and rupture of giant gastric stromal tumor (> 30 cm) in a young patient. World J. Surg. Oncol. 2008; 6: 76.
49. Armbrust T., Sobotta M., Ramadori G.: Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with imatinib. Ann. Oncol. 2007; 18(6): 1123-1125.
50. Bogoevski D., Mann O., Schurr P., Izbicki J., Strate T.: Laparoscopic gastric tailoring for huge subcardial gastrointestinal stromal tumor. JSLS 2007; 11(3): 394-397.
51. Osada T., Nagahara A., Kodani T. et al.: Gastrointestinal stromal tumor of the stomach with a giant abscess penetrating the gastric lumen. World J. Gastroenterol. 2007; 13(16): 2385-2387.
52. Efremidou E., Liratzopoulos N., Papageorgiou M., Romanidis K., Manolas K., Minopoulos G.: Perforated GIST of the small intestine as a rare cause of acute abdomen: surgical treatment and adjuvant therapy. Case report. J. Gastrointestin. Liver Dis. 2006; 15(3): 297-299.
53. Ferraresi V., Catricala C., Ciccarese M., Ferrari A., Zeuli M., Cognetti F.: Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. Anticancer Res. 2006; 26(6C): 4771-4774.
54. Lai I., Hu R., Chang K.: Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors. Hepatogastroenterology 2005; 52(63): 826-828.
55. Cunningham S., Shibata D., Volpe C.: Isolated abdominal wound metastasis from a gastrointestinal stromal tumor. Int. J. Gastrointest. Cancer 2003; 33(2-3): 129-132.
56. Online: http://www.clinicaltrials.gov/ct2/show/NCT00867113... (Access: march 2012).
57. Online: http://www.clinicaltrials.gov/ct2/show/NCT01172548... (Access: march 2012).
58. Online: http://www.clinicaltrials.gov/ct2/show/NCT00103168... (Access: march 2012).
59. Online: http://cancer.gov/clinicaltrials/search/view?cdrid=410825&version= healthprofessional (Access: march 2012)
60. Nilsson B., Bümming P., Meis-Kindblom J. et al.: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer 2005; 103(4): 821-829.
61. DeMatteo R., Lewis J., Leung D., Mudan S., Woodruff J., Brennan M.: Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000; 231(1): 51-57.
62. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. National Institute for Health and Clinical Excellence (NICE) technology appraisal guidance 196. Sierpień 2010.
63. Online: http://www.novartis.com/newsroom/media-releases/en/2012/1579137.shtml (Access: march 2012).
64. von Mehren M., Benjamin R., Bui M. et al.: NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 2.2011.
65. Hou Y., Grabellus F., Weber F. et al.: Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection. J. Gastrointest. Surg. 2009; 13(9): 1583-1592.
66. Heinrich M., Corless C., Demetri G. et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21(23): 4342-4349.